Research Contract

Proteome Sciences plc

Proteome Sciences Closes Biomarker Contract with Janssen

20th December 2010  Proteome Sciences plc (AIM:PRM) is pleased to announce that it has entered into a research contract with Janssen Pharmaceutica NV, a J&J company ("Janssen"). PS Biomarker Services™ will use a combination of its proprietary TMT® isobaric mass tag technology, sample preparation and bioinformatics with state of the art Orbitrap Velos mass spectrometry for the analysis of samples provided in the J&J contract. 

Commenting on the collaboration Christopher Pearce, Chief Executive of Proteome Sciences said:

"We are delighted to add Janssen, to the growing list of PS Biomarker Services™ clients. As a global pharmaceutical company, Janssen has the opportunity to select from many contract service organisations and they have recognised the advantages of using our unique TMT® and peptidomic workflows and Proteome Sciences' strong track record of delivery in biomarker discovery, validation and rapid MS assay development."

Ends

For further information please contact:

Proteome Sciences plc

www.proteomics.com Tel: +44 (0)1932 865065

Christopher Pearce, Chief Executive Officer christopher.pearce@proteomics.com 

James Malthouse, Finance Director james.malthouse@proteomics.com 

Dr. Ian Pike, Chief Operating Officer ian.pike@proteomics.com 

Dr. Rainer Voegeli, Commercial Director rainer.voegeli@proteomics.com

Nominated Adviser

Singer Capital Markets Limited

Shaun Dobson/Claes Spång

Tel: +44 (0)20 3205 7500

Public Relations

IKON Associates Redleaf Communications Limited

Adrian Shaw Anna Dunkin/Lucy Salaman

Tel: +44 (0)1483 535102 Tel: +44 (0)20 7566 6700

Mobile: +44 (0)7979 900733 Email: proteome@redleafpr.com 

Email: adrian@ikonassociates.com

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and uses high sensitivity proprietary technologies for protein biomarker discovery, validation and assay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications. These biomarkers are available for outlicensing. The first blood test for lung cancer using Proteome Sciences' biomarkers was launched in the USA in 2009 and received Medicare reimbursement in 2010. Its PS Biomarker Services provides ISO 9001: 2008 accredited facilities in Frankfurt, Germany, using proprietary isobaric and isotopic Tandem Mass Tags® (TMT®) to discover protein biomarkers, and reference materials combined with isotope dilution mass spectrometry. Highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in validation studies. Assays for validated biomarkers can be transferred for immunoassay development. Proteome Sciences, based in Cobham, UK, has facilities in London and Frankfurt and delivers outsourced proteomics services and proprietary biomarkers to pharmaceutical, biotechnology and diagnostics companies. Visit http://www.proteomics.com.